Diana E. Lake, MD
Breast Oncologist
My Role at MSKWe post reviews for MSK healthcare providers who have at least 30 patient experience surveys completed. If you do not see reviews for a provider, it may be because they do not yet have enough survey responses, or the provider may not be part of the group of healthcare providers included in the survey.
Only outpatient providers are included in the survey. Healthcare providers who only work in the hospital or in urgent care are not included in the survey. Pathologists or researchers who do not provide direct care to patients do not have reviews.
Request an Appointment
About Me
- Attending Physician
I am a medical oncologist with a practice that is devoted solely to the care of people with breast cancer.
My research interests involve all areas of breast cancer but focus mainly on the development of new therapies, prevention of cancer recurrence following surgery, and treatment of recurrent disease. Working in conjunction with my colleagues on the Breast Medicine Service, and in breast, surgical, and radiation, and as the liaison in breast medicine to Cancer and Leukemia Group B (a national clinical trial cooperative research group sponsored by the National Cancer Institute), I am involved in clinical trials to develop better hormonal therapies and improved approaches to treatment before surgery. In addition, I am a member of the National Institutes of Health (NIH) Scientific Review Committee, and I previously served on the NIH Cooperative Group Review and its Cancer Education committees.
A breast oncologist is a doctor with special training in breast cancer.
My Specialties
- Breast Cancer
Education
- MD, Chicago Medical School
Residencies
- Pathology - New York Hospital/Cornell University Medical College
- Internal Medicine - North Shore University Hospital
Fellowships
- Hematology/Oncology - Memorial Sloan Kettering Cancer Center
Board Certifications
- Internal Medicine
- Medical Oncology
- Hematology
Insurance Information
Understanding your insurance options is an important part of managing your cancer care. We have relationships with many common healthcare providers and plans.
In Network Coverage Type
HMO, PPO
In Network Coverage Type
HMO, EPO PPO, POS
In Network Coverage Type
PPO, POS, HMO
MSK has a tentative agreement with Cigna to continue coverage in 2024.
In Network Coverage Type
PPO, POS, EPO, HMO
Offers a qualified health plan from the Health Insurance Marketplace. Call Emblem to learn more.
In Network Coverage Type
PPO
In Network Coverage Type
HMO, EPO
Offers a qualified health plan from the Health Insurance Marketplace. Call Fidelis to learn more.
In Network Coverage Type
EPO, HMO, PPO, POS
Offers a qualified health plan from the Health Insurance Marketplace. Call Healthfirst to learn more.
In Network Coverage Type
EPO
In Network Coverage Type
EPO
In Network Coverage Type
Federal Government
In Network Coverage Type
PPO, POS, EPO, HMO
In Network Coverage Type
State Government
Don't see your carrier or plan? We can help you understand your coverage.
If you don't have health insurance or are worried that your care may not be fully covered, our financial assistance programs may be able to help.
If you have questions about insurance, call us at 646-497-9176.
Make an Appointment
New Patients
Current Patients
Contact and Location
Dr. Lake sees patients at one location.
Looking to see a doctor at a different location? See all MSK locations.
Colleagues
Doctors at Memorial Sloan Kettering work as teams, with specialists from all different areas. I work closely with nurse practitioner Danielle Alleva. We combine our expertise to provide comprehensive care to our patients at every step of their cancer journey.
Clinical Trials
Memorial Sloan Kettering's doctors and scientists are constantly developing new treatments for cancer. MSK is typically running hundreds of clinical trials at a given time.
You may be able to participate in a clinical trial even if you are new to MSK. Search our online directory to find trial information and see more about who can participate.
Search clinical trialsResearch and Publications
Read more
Goldenberg D, Sharkey R, Hall T, Mortly S, Siegel, Izon D, Swayne C, Lake D, Hansen H, Pinsky C. Radio-immunotherapy of B-Cell lymphomas with 131-I-labeled L12 (EPB-2) monoclonal antibody. Antibody Immunoconjugate Radio-pharmaceuticals 1991; 4: 763-769.
Kris MG, Pablo D, Gralla RJ, Burke T, Prestifilippo J, Lake-Lewin D. Pulmonary toxicity following vinblastine administration in patients receiving mitocycin plus vinca alkaloid combination therapy. Cancer Treat Reports 68, 1019-1031.
Yen A, Lake-Lewin D. Uncoupling lymphocyte proliferation from differentiation:dissimilar dose response relations pokeweek mitogen induced proliferation and differentiation of normal human lymphocytes. Cellular Immunol 1981; 61: 332, 1981.
Visit PubMed for a full listing of Dr. Lake’s journal articles. Pubmed is an online index of research papers and other articles from the US National Library of Medicine and the National Institutes of Health.
See all on PubMedPatient Reviews
Your trust is our main concern
We strive to keep reviews trustworthy, honest and fair. Learn more about our patient experience reviews.
Disclosures
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Diana E. Lake discloses the following relationships and financial interests:
No disclosures meeting criteria for time period
If you’re a patient at MSK and would like more information about your doctor’s external relationships, please talk with your doctor.
The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2022 through disclosure submission in spring 2023). This data reflects interests that may or may not still exist. This data is updated annually.
Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].
